Skip to main content
OpenTrials
Completed

NCT Number: NCT05974397

Nationwide Trends in Incidence, Healthcare Utilization, and Mortality in Hospitalized Acute Myocardial Infarction Patients in Taiwan

This was a retrospective study using the Taiwan's National Health Insurance Research Database (NHIRD). The study employed two study designs for different purposes as follows:

* A cross-sectional analysis was conducted to explore the annual incidence trends. * A longitudinal cohort study was conducted to assess baseline characteristics, treatment patterns, long-term healthcare utilization, and cause-specific mortality among incident AMI patients.

In each part, the study was conducted for AMI, and separately for ST-segment elevation and non-ST- segment elevation myocardial infarction (STEMI and NSTEMI)

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Acute Myocardial Infarction

Age range

20 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Novartis

Taipei, Taiwan

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Cross-sectional analysis:

  • Patients aged 20 years and older.
  • Patients who had been admitted for AMI, defined as primary or first secondary diagnosis of AMI between 2014 and 2020.
  • The diagnosis of AMI/ STEMI/ NSTEMI was identified by the International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) codes and 10th revision (ICD-10-CM) codes.
  • Incident cases of AMI hospitalization were defined as no history of AMI-related hospitalization or outpatient visit within 1 year before admission.

Longitudinal analysis:

Patients aged 20 years and older.

  • Patients who had been admitted for AMI, defined as primary or first secondary diagnosis of AMI between 2014 and 2017.
  • The diagnosis of AMI/ STEMI/ NSTEMI was identified by ICD-9-CM codes and ICD-10-CM codes. (The ICD-9-CM code and ICD-10-CM codes were the same as above)
  • Incident cases of AMI hospitalization were defined as no history of AMI-related hospitalization or outpatient visit within 1 year before admission.
  • The cohort entry date was defined as the admission date of incident AMI hospitalization, and the index date was defined as the discharge date of incident hospitalization.

Exclusion criteria

None specified

Treatment and study plan

Primary outcomes

  1. Mean age of patients

    Time frame: 12 months

  2. Number of male patients

    Time frame: 12 months

  3. Year of patient entry into cohort

    Time frame: 12 months

  4. Number of patients with AMI in Taiwan

    Time frame: 12 months

  5. Number of patients with STEMI in Taiwan

    Time frame: 12 months

  6. Number of patients with NSTEMI in Taiwan

    Time frame: 12 months

  7. Number of AMI patients with comorbidities

    Time frame: Up to 3 years

  8. Number of patients with treatment for AMI

    Time frame: Up to 3 years

  9. Number of STEMI patients with comorbidities

    Time frame: Up to 3 years

  10. Number of patients with treatment for STEMI

    Time frame: Up to 3 years

  11. Number of NSTEMI patients with comorbidities

    Time frame: Up to 3 years

  12. Number of patients with treatment for NSTEMI

    Time frame: Up to 3 years

  13. Number of mortalities among AMI patients

    Time frame: Up to 3 years

  14. Number of mortalities among STEMI patients

    Time frame: Up to 3 years

  15. Number of mortalities among NSTEMI patients

    Time frame: Up to 3 years

  16. Number of AMI patients with outpatient visits

    Time frame: Up to 3 years

  17. Number of AMI patients with emergency room visits

    Time frame: Up to 3 years

  18. Number of AMI patients with hospitalizations

    Time frame: Up to 3 years

  19. Length of hospital stay for AMI patients

    Time frame: Up to 3 years

  20. Direct medical costs for AMI patients

    Time frame: Up to 3 years

  21. Number of STEMI patients with outpatient visits

    Time frame: Up to 3 years

  22. Number of STEMI patients with emergency room visits

    Time frame: Up to 3 years

  23. Number of STEMI patients with hospitalizations

    Time frame: Up to 3 years

  24. Length of hospital stay for STEMI patients

    Time frame: Up to 3 years

  25. Direct medical costs for STEMI patients

    Time frame: Up to 3 years

  26. Number of NSTEMI patients with outpatient visits

    Time frame: Up to 3 years

  27. Number of NSTEMI patients with emergency room visits

    Time frame: Up to 3 years

  28. Number of NSTEMI patients with hospitalizations

    Time frame: Up to 3 years

  29. Length of hospital stay for NSTEMI patients

    Time frame: Up to 3 years

  30. Direct medical costs for NSTEMI patients

    Time frame: Up to 3 years

Sponsors and collaborators

Lead sponsor

Novartis Pharmaceuticals

Industry

Registry information

Important dates

Study start
2021
Primary completion
2022
Study completion
2022
First posted
Aug 3, 2023
Registry last updated
Aug 3, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.